Moderna’s mRNA-based flu vaccine shows promise in early-stage study

This post was originally published on this site

The early-stage study is ongoing and a mid-stage study testing of the vaccine, mRNA-1010, is now fully enrolled, the company said.

This data, though limited, puts Moderna ahead of other drugmakers, including rival Pfizer Inc (NYSE:PFE), that are also testing their flu vaccine based on messenger RNA.

Moderna also said it was developing a pan-respiratory annual booster vaccine, which would target multiple viruses including COVID-19, flu and Respiratory syncytial virus.

The new vaccine, mRNA-1345, has demonstrated positive early-stage results, it said.

“Even before the COVID-19 pandemic, approximately three million people died each year due to respiratory infections … our goal is to limit this suffering with an annual pan-respiratory single dose booster vaccine,” Chief Executive Officer Stéphane Bancel said.